Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED -3.51%74 3-Year EBITDA Growth Rate is 8.60% as of Jun. 2026, which is 341% above its 10-year median of 1.95. GuruFocus rates XTER:MED with a GF Score™ of 74/100 and a GF Value™ of €3.14 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 526 Healthcare Providers & Services companies, MediClin AG ranks worse than 52.66% on this metric.
During the past 12 months, MediClin AG's average EBITDA Per Share Growth Rate was 5.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 8.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of MediClin AG was 141.20% per year. The lowest was -54.50% per year. And the median was 1.95% per year.
MediClin AG (XTER:MED) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
MediClin AG 3-Year EBITDA Growth Rate Related Terms
XTER:MED vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, MediClin AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where MediClin AG's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 8.60% mean?
MediClin AG (XTER:MED) has a 3-Year EBITDA Growth Rate of 8.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MediClin AG and its competitors. This is 341% above median its historical median of 1.95. According to the industry distribution chart, MediClin AG ranks #277 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 52.7%.
Is MediClin AG's 3-Year EBITDA Growth Rate too high?
MediClin AG's current 3-Year EBITDA Growth Rate of 8.60% is 341% above median its 10-year median of 1.95. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. MediClin AG's value of 8.60% is 14.4% below this industry median. Based on the distribution chart, MediClin AG ranks #277 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MediClin AG has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #277 out of 526 companies for 3-Year EBITDA Growth Rate. This places MediClin AG in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. MediClin AG's value of 8.60% is 14.4% below this benchmark. While the company's 10-year median is 1.95 vs. the industry median of 10.05, MediClin AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediClin AG's current 3-Year EBITDA Growth Rate of 8.60% is 14.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MediClin AG and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediClin AG's current 3-Year EBITDA Growth Rate is 8.60%, which is 341% above median its own 10-year median of 1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.14, compared to a current price of €5.35 — trading 70.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 8.60%, which is 341% above median its 10-year median of 1.95 and 14.4% below the Healthcare Providers & Services industry median of 10.05. MediClin AG's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current 3-Year EBITDA Growth Rate is 8.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €5.35 is trading 70.4% above its estimated GF Value™ of €3.14.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
3-Year EBITDA Growth Rate: 8.60% (341% above median its 10-year median of 1.95)
GF Value™: €3.14 vs. price of €5.35 (70.4% above fair value)
Industry Position: 14.4% below the Healthcare Providers & Services median (#277 of 526)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG is a German healthcare provider that operates acute care hospitals, rehabilitation clinics, and nursing care facilities. Its operations are organized into Post-acute, Acute, Nursing care, and Service segments. The Post-acute segment, which generates the majority of revenue, focuses on follow-up rehabilitation and curative treatment, with some facilities also providing acute neurology and acute psychosomatics. The Acute segment covers neurology, neurological early rehabilitation, psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time, part-time, and daycare nursing services, while the Service segment provides centralized support functions. MediClin serves patients primarily in Germany through its network of clinics and care centers, generating revenue mainly from inpatient and outpatient medical treatment and care services, reimbursed by statutory and private health insurers. The company is headquartered in Offenburg, Germany.
74GF Score
Get the complete analysis for XTER:MED
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
